Abbott/TAP joint venture readjusts 2004 sales expectations due to a reported 7% year-to-date decline in the Rx PPI market. Prilosec OTC has "probably had more of an impact on the branded side than anticipated, or at least the impact has lasted longer," says Abbott Divisional VP-Investor Relations John Thomas in a July 9 earnings call. TAP now expects full-year Prevacid sales to decrease by around 10%, according to Abbott, and will attempt to reinvigorate the brand by targeting adolescents and launching new formulations such as the recently approved Prevacid SoluTab Orally Disintegrating Tablets. SoluTabs provide "flexibility and convenience, especially in children and other patients that have difficulty swallowing," states Abbott VP-Investor Relations & Public Affairs Catherine Babington. The firm expects the branded PPI market will grow "at a more modest rate" in the second half of 2004...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.